Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725382 | 0.81 | CHRM1 (0.52) | CNR1CHRM1 | |
| SCHEMBL18756055 | 0.81 | CHRM1 (0.52) | CNR1CHRM1 | |
| SCHEMBL29934007 | 0.77 | CNR1 (0.49) | CNR1CNR2TDO2 | |
| SCHEMBL2224924 | 0.77 | CNR2 (0.51) | CNR1CNR2TDO2KMT2ASCN9A | |
| SCHEMBL2224921 | 0.77 | CNR2 (0.51) | CNR1CNR2TDO2KMT2ASCN9A | |
| SCHEMBL2269430 | 0.77 | CNR2 (0.51) | CNR1CNR2TDO2KMT2ASCN9A | |
| SCHEMBL2222196 | 0.77 | CNR2 (0.51) | CNR1CNR2TDO2KMT2ASCN9A | |
| SCHEMBL18725403 | 0.77 | CNR2 (0.52) | CNR1CNR2TDO2CHRM1 | |
| SCHEMBL18756569 | 0.75 | CHRM1 (0.61) | CNR1CHRM1 | |
| SCHEMBL18725458 | 0.75 | CHRM1 (0.61) | CNR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CNR1 27/4885CNR2 55/4885TDO2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.